Cadila Healthcare
-
January 15, 2021, Friday
Here is a derivative strategy for Cadila Health by Vinay Rajani of HDFC Sec
The stock price of Cadila Healthcare has broken out from the consolidation which held for last three weeks
-
January 04, 2021, Monday
Stocks to watch: RCFL, Tata Motors, RIL, BEML, Cadila Health, Adani Green
Tata Motors reported a 21 per cent increase in total vehicle sales in the domestic market to 53,430 units in December
-
November 12, 2020, Thursday
Cadila Healthcare completes phase-2 trial of Hepatitis C drug for Covid-19
95% subjects in the test who received a single dose of PegiHepTM along with SOC became virus free as assessed by RT-PCR on day ...
-
November 06, 2020, Friday
Indices rally for 5th straight day, Sensex up 553 pts; RIL, financials gain
All that happened in the markets today
-
November 03, 2020, Tuesday
Cadila Healthcare rallies 9% on strong September quarter results
In Q2FY21, Cadila's Ebitda margins improved by 370 basis points at 22.6% against 18.9% in Q2FY20.
-
October 29, 2020, Thursday
Govt to prioritise Covid-19 vaccine for front line health workers: Report
The national vaccine distribution plan is being formulated with the assumption that limited volumes of the inoculation will be ...
-
October 27, 2020, Tuesday
Cadila scouts partners to ramp up Covid vaccine production by 50 to 70 mn
The Ahmedabad-based firm is looking to hire contract manufacturers for an additional 50 million to 70 million doses of its ...
-
October 08, 2020, Thursday
Cadila: Rebound in domestic formulations to add to US sales, drive earnings
In the US, Cadila is expected to gain from improvement in realisation for its product range led by drug shortages
-
October 08, 2020, Thursday
Cadila Healthcare rises 4% on launch of pressurized Metered Dose Inhaler
Forglyn pMDI is priced at Rs 495 per pack and has been developed in-house using Zydus' innovations in formulation technology
-
August 30, 2020, Sunday
Covid-19 prescription: Pharma players shift their focus over the counter
The pandemic pushes pharma companies to look at drugs that held promise in transitioning to over the counter segment
